Regeneron Pharmaceuticals issued supplementary information detailing the rationale and design of its 2026 performance share unit program; the compensation committee approved the plan as part of a multi-year effort to maximize value amid pipeline growth. Market relevance: outlines specific performance metrics regarding new drug filings and annual net product sales.